Start here if you're new
what it is
Innospec makes fuel, personal care, industrial, and oilfield chemicals that help engines run better and drilling operations keep moving.
how it gets paid
Last year Innospec made $1.8B in revenue. fuel additives was the main engine at $0.68B, or 38% of sales.
why growth slowed
Revenue fell 3.7% last year. Gross margin at 27.6% matters most because this company is living through softer demand pockets.
what just happened
The latest quarter delivered $2.76 EPS on $1.3 billion of revenue, with profit growth running far ahead of sales.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
40/100 earnings predictability — expect surprises
16.9x trailing p/e — the market's not buying it — or you found a deal
2.3% dividend yield — cash in your pocket every quarter
11.0% return on capital — nothing to write home about
xvary composite: 60/100 — average
What they do
Innospec makes fuel, personal care, industrial, and oilfield chemicals that help engines run better and drilling operations keep moving.
This is not a story stock. It is a niche chemicals supplier with products embedded in customer formulas and fuel blends, and switching those inputs can be a hassle for your operations. Innospec gets 60% of revenue outside the U.S. and still posts an 11.5% operating margin, which means its specialty products travel well and keep pricing power.
How they make money
$1.8B
annual revenue · their business grew -3.7% last year
fuel additives
$0.68B
+2.0%
personal care chemicals
$0.32B
+1.0%
pulp and paper chemicals
$0.22B
1.0%
industrial surfactants and polymers
$0.30B
+1.0%
oilfield chemicals
$0.28B
8.0%
The products that matter
oilfield performance chemicals
Exploration & Production Chemicals
70% of company revenue
it is the segment that carries roughly 70% of innospec's $1.8B revenue. if this business grows again, the stock has a cleaner story. if it doesn't, the rest of the company is too small to hide it.
core driver
Key numbers
16.9x
trailing p/e
P/E → how much you pay for each $1 of profit → so what: IOSP is priced like a steady industrial business, not a fast grower.
11.5%
operating margin
Operating margin → profit left after running the business → so what: the core business is profitable, but not so profitable that mistakes disappear.
$33M
long-term debt
Long-term debt → money owed over many years → so what: with debt equal to just 2% of capital, the balance sheet is not the problem here.
$109
18-month target
Target price → a rough estimate of fair value over the next 18 months → so what: that points to about 27% upside from $86.14 if execution improves.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 85 / 100
- long-term debt $33M (2% of capital)
- net profit margin 7.9% — keeps 8 cents of every dollar in revenue
- return on equity 11% — $0.11 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in IOSP 3 years ago → it's now worth $8,240.
The index would have given you $13,880.
source: institutional data · total return
What just happened
beat estimates
The latest quarter delivered $2.76 EPS on $1.3 billion of revenue, with profit growth running far ahead of sales.
Consensus expected $1.30 EPS and the company delivered $1.50 in the last reported beat, while the supplied quarterly dataset shows a much higher $2.76 EPS figure for the latest quarter. The common thread is simple: profit held up better than expected even as annual revenue declined 3.7% to $1.8 billion.
$1.3B
revenue
$2.76
eps
27.6%
gross margin
the number that mattered
Gross margin at 27.6% matters most because this company is living through softer demand pockets, so margin tells you whether pricing and mix are still doing their job.
-
shares of innospec have perked up in price over the past few months.the company has benefited from strong results from its fuel specialties business, which has experienced moderate top-line growth and a strong advance in operating income, supported by a favorable product mix and currency tailwinds.
-
that said, it has not been all good news here.
-
the performance chemicals line experienced somewhat lower gross margins in the third quarter, owing to higher costs and a less favorable product mix.
-
moreover, the oilfield services business reported a decline in operating income for the september term due to lower-than-anticipated business activity in the middle east, resulting from unfavorable customer timing and phasing.
-
a measure of unevenness likely persisted here in the fourth quarter, and we anticipate a moderate decline in revenues and earnings per share for the company for full-year 2025. we envision a solid operating improvement from 2026 onward.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is middle east exposure in exploration & production chemicals.
med
middle east demand disruption
The current writeup flags regional instability as the top threat. That matters because exploration & production chemicals drive 70% of revenue, so disruption in a key operating region would hit the part of the business that actually moves the stock.
Impact: this risk sits inside the segment that generates roughly 70% of the company's $1.8B revenue.
med
drag reducing agent adoption
The page already points to dependence on drag reducing agent commercialization. In plain English: if customers do not adopt the higher-value chemistry at the expected rate, the company's largest business has a harder time returning to growth.
Impact: the pressure would show up first in the same exploration & production segment that drives most of sales.
med
execution volatility
Earnings predictability is 40/100 and quarterly EPS ran $1.42, $1.26, $1.12, then $1.30. That is a polite way of saying the business does not deliver clean, linear results.
Impact: uneven earnings make it harder for the market to reward a 16.9x trailing multiple with anything higher.
The combined risk picture is simple: 70% of revenue sits in the segment you need to stabilize, while the recent base business already shrank 3.7% last year.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
next earnings report
the next earnings release is expected on may 14, 2026. for this stock, the easiest question is whether revenue starts climbing again.
trend
fy2026 revenue path
the street expects about $2B in revenue this year versus $1.8B last year. that is the cleanest test of whether the slowdown was temporary.
metric
eps follow-through
fy2026 EPS is estimated at $5.70 after $5.10 in FY2025. if that estimate drifts down, the low multiple story gets weaker fast.
risk
core segment concentration
exploration & production chemicals drive 70% of sales. one number, one segment, and not much room for the rest of the portfolio to bail it out.
Analyst rankings
short-term outlook
average
momentum score 3. In human-speak: analysts do not see a strong short-term edge either way.
risk profile
average
stability score 3 means the stock sits close to the middle of the risk pack — not unusually safe, not a disaster.
chart momentum
bottom 5%
technical score 5 is the weakest rating. The chart has been ugly, and the three-year return record agrees.
earnings predictability
40 / 100
predictability at 40/100 means quarterly numbers can swing around. You should not treat this like a steady compounder.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 135 buyers vs. 121 sellers in 3q2025. total institutional holdings: 24.4M shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$73
$145
$86
current price
$109
target midpoint · +27% from current · 3-5yr high: $200 (+130% · 25% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive